The Intellectual Property & Science business of Thomson Reuters unveiled the nominations for the Allicense 2014 Breakthrough Awards for Deal of the Year, honouring the top global deal in each of two categories: 'Biopharmaceutical Licensing' and 'Mergers and Acquisitions' (M&A), as identified by Thomson Reuters Recap, the premier analysis tool for biopharmaceutical business deal making. The awards - to be determined by public vote - will be presented on April 29 at Allicense, a prominent event connecting business development, licensing and M&A professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical development.
The award nominees, five contenders in each of the two categories: Licensing and M&A, were determined by Thomson Reuters deals analysts after a thorough analysis of Recap information and other criteria that examined hundreds of deals negotiated throughout 2013. Members of the pharmaceutical community are invited to choose the top breakthrough deals in each category by submitting a ballot by end of day April 25.
Interested parties may visit the Allicense website to view in-depth details on each of the nominated deals, as well as to cast their vote for the Deal of the Year. Online voting ends April 25, with live voting taking place at the Allicense conference until 5 p.m. PDT on April 29.
Allicense 2014 is the world's premier event for deal making, licensing and business development. Industry professionals discuss key issues facing the sector and learn about innovative deals and structures of the future. Allicense 2014 is scheduled for April 29, April 30, in San Francisco, California.
